Caas Capital Management LP Replimune Group, Inc. Transaction History
Caas Capital Management LP
- $288 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding REPL
# of Institutions
153Shares Held
70MCall Options Held
26.7KPut Options Held
28.6K-
Baker Bros. Advisors LP New York, NY10MShares$120 Million1.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.24MShares$110 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA5.56MShares$66.2 Million3.26% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.87MShares$57.9 Million6.46% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$56.1 Million0.0% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $587M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...